Clinical trials: Patients With Thyroid Cancer
Differentiated Thyroid Carcinoma
Study of ST-1898 in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer
ST-1898, a multi-targeted tyrosine kinase inhibitor, has demonstrated strong inhibitory activity for VEGFR2, c-MET, AXL, PDGFRA, RET, KIT, etc.
- Trial name
- NCT06359847
- Testing
- ST-1898 tablets
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing Scitech-Mq Pharmaceuticals Limited
Adenocarcinoma, Adenocystic Carcinoma
The Registry of Oncology Outcomes Associated With Testing and Treatment
This study is to collect and validate regulatory-grade real-world data (RWD) in oncology using the novel, Master Observational Trial construct. This data can be then used in real-world evidence (RWE) generation.
- Conditions
- Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer, Appendix Cancer
- Trial name
- ROOT (NCT04028479)
- Testing
- Biomarker Testing (L), Systemic Treatment (T), Patient Reported Outcomes (P)
- Where
- 2 sites in United States
- Volunteers
- 167 people
- Sponsor
- Taproot Health
Anaplastic Thyroid Cancer, Recurrent Thyroid Cancer
Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer
This phase II trial is studying how well sorafenib works in treating patients with advanced anaplastic thyroid cancer. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by…
- Trial name
- NCT00126568
- Testing
- sorafenib tosylate
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Differentiated Thyroid Cancer
Initial Management in Patients With Differentiated Thyroid Cancer in the Real World in China
To find out the gap between real-world clinical practice and guideline recommendations in initial management of DTC patients To observe the characteristics of patients who achieved and did not achieve TSH target value after one…
- Trial name
- DTCC (NCT02638077)
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Huazhong University of Science and Technology
Anaplastic Thyroid Cancer
Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer
This pilot phase 2 study evaluate the effectiveness and safety of pembrolizumab and lenvatinib in patients with anaplastic thyroid cancer.
- Trial name
- NCT06374602
- Testing
- Pembrolizumab + Lenvatinib
- Where
- Russia
- Volunteers
- 20 people
- Sponsor
- Saint Petersburg State University, Russia
Non-Small Cell Lung Cancer, Medullary Thyroid Cancer
Phase I/II Study of SY-5007, a RET Inhibitor, in Patients With RET-altered Advanced Solid Tumor
This is a phase I/II, open-label, multi-center, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of SY-5007 administered orally to participants with…
- Conditions
- Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Solid Tumor
- Trial name
- NCT05278364
- Testing
- SY-5007
- Where
- 2 sites in China
- Volunteers
- 184 people
- Sponsor
- Shouyao Holdings (Beijing) Co. LTD
Head and Neck Cancer
Study of ABT-510 (Thrombospondin Analogue) in Patients With Advanced Head and Neck Cancer
The goals of this clinical research study are to see how individuals with advanced head and neck cancer respond to treatment with the new drug thrombospondin (ABT-510) and to learn how effective it is in destroying cancer cells.
- Trial name
- NCT00113334
- Testing
- ABT-510
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- M.D. Anderson Cancer Center
Thyroid Cancer, Thyroid Nodules
ctDNA in Patients With Thyroid Nodules
When the DNA inside of human cells undergoes certain alterations (mutations), the cells may develop into a cancer. The cancer cells may shed this DNA into the blood stream.
- Conditions
- Thyroid Cancer, Thyroid Nodules, Thyroid Adenoma, Thyroiditis
- Trial name
- NCT02778412
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Pathway Genomics
Hypertension, Depression
Patient-Centred Innovations for Persons With Multimorbidity - Quebec
The aim of Patient-Centred Innovations for Persons With Multimorbidity (PACE in MM) study is to reorient the health care system from a single disease focus to a multimorbidity focus; centre on not only disease but also the…
- Conditions
- Hypertension, Depression, Anxiety, Musculoskeletal Pain
- Trial name
- PACEinMM-QC (NCT02789800)
- Testing
- DIMAC02
- Where
- 2 sites in Canada
- Volunteers
- 284 people
- Sponsor
- Université de Sherbrooke
Head and Neck Cancer
Celecoxib in Treating Patients With Progressive Metastatic Differentiated Thyroid Cancer
RATIONALE: Celecoxib may stop the growth of thyroid cancer by stopping blood flow to the tumor and by blocking the enzymes necessary for tumor cell growth.
- Trial name
- NCT00061906
- Testing
- celecoxib
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Thyroid Gland Anaplastic Carcinoma, Poorly Differentiated Thyroid Carcinoma
[177Lu]Lu-AKIR001 First-in-human Study
The goal of this clinical trial is to evaluate the safety and tolerability of increasing doses of [177Lu]Lu-AKIR001, both in relation to tolerable activity of lutetium-177 and the absorbed protein mass dose of AKIR-001 in…
- Conditions
- Thyroid Gland Anaplastic Carcinoma, Poorly Differentiated Thyroid Carcinoma, Cancer Head and Neck, Cervix Carcinoma
- Trial name
- AKIR001 (NCT06639191)
- Testing
- [177Lu]Lu-AKIR001
- Where
- Sweden
- Volunteers
- 15 people
- Sponsor
- Karolinska University Hospital
Leukaemia (Chronic)
What is the Impact of TKI on Thyroid Function in CML Patients?
Evaluation of the impact of various TKI on thyroid function in patients diagnosed with cml
- Trial name
- NCT07200882
- Volunteers
- 76 people
- Sponsor
- Assiut University
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)
This phase II MATCH treatment trial identifies the effects of trametinib and dabrafenib in patients whose cancer has genetic changes called BRAF V600 mutations.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
- Trial name
- NCT04439292
- Testing
- Dabrafenib Mesylate, Trametinib Dimethyl Sulfoxide
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumor, Adult, Advanced Solid Tumor
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101, a novel anti VISTA IgG1 monoclonal antibody as monotherapy or in combination with cemiplimab in patients with…
- Conditions
- Solid Tumor, Adult, Advanced Solid Tumor, Head and Neck Cancer, Breast Cancer
- Trial name
- NCT05864144
- Testing
- SNS-101 (anti-VISTA), Cemiplimab
- Where
- 10 sites in United States
- Volunteers
- 98 people
- Sponsor
- Sensei Biotherapeutics, Inc.
Lenvatinib Treatment
Using Chronobiology to Improve Lenvatinib Efficacy
The goal of this proof-of-concept clinical trial is to assess the efficacy and safety of chronobiology implementation into lenvatinib treatment regimens of thyroid cancer patients, via a mobile application.
- Trial name
- NCT06321120
- Testing
- variability-based lenvatinib regimen
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- Hadassah Medical Organization
Hypothyroidism, Hyperthyroidism/Thyrotoxicosis
Evaluation of Different Diagnostic Therapeutic Strategies in Patients with Thyroid Pathology
Observational single-center prospective and retrospective, nonpharmacological, spontaneous cohort study.
- Conditions
- Hypothyroidism, Hyperthyroidism/Thyrotoxicosis, Thyroid Nodule (Benign), Thyroid Carcinoma
- Trial name
- NCT06779747
- Where
- Italy
- Volunteers
- 5,850 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Mesothelioma, Bladder Cancer
Safety Study of MGD009 in B7-H3-expressing Tumors
The purpose of this study is to evaluate the safety of MGD009 when given to patients with B7-H3-expressing tumors. The study will also evaluate what is the highest dose of MGD009 that can be given safely.
- Conditions
- Mesothelioma, Bladder Cancer, Melanoma, Squamous Cell Carcinoma of the Head and Neck
- Trial name
- NCT02628535
- Testing
- MGD009
- Where
- 20 sites in United States, Australia and 1 more
- Volunteers
- 67 people
- Sponsor
- MacroGenics
Differentiated Thyroid Cancer
Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer
The study is designed to evaluate the clinical efficacy, safety and tolerability of selumetinib with radioactive iodine therapy in patients with differentiated thyroid cancer.
- Trial name
- ASTRA (NCT01843062)
- Testing
- Selumetinib, Radioactive Iodine Therapy
- Where
- 45 sites in United States, Brazil and 6 more
- Volunteers
- 233 people
- Sponsor
- AstraZeneca
Thyroid Cancer
Potential Role for Carbon Nanoparticles to Guide Central Neck Dissection in Patients With Papillary Thyroid Cancer
Papillary thyroid cancer (PTC) is the most common subtype of thyroid cancer. The most common site of PTC nodal metastases is the central neck, which has a reported rate of lymph node metastases as high as 50%~70%.
- Trial name
- NCT02724176
- Testing
- carbon nanoparticles
- Volunteers
- 140 people
- Sponsor
- Peking University Cancer Hospital & Institute